(Alliance News) - Genflow Biosciences PLC shares jumped on Wednesday, after it said it has submitted an application for trading of its shares on the OTCQB Venture Market in the US.

Genflow is a London-based biotechnology company focused on longevity, with research & development facilities in Belgium. Its shares were up 22% to 5.36 pence each in London on Wednesday afternoon.

Genflow said that trading on the OTCQB market will allow it to access "one of the world's largest investment markets" and expand its reach to a broader pool of investors. It noted that 61.5% of the world's longevity-focused companies are located in the US, compared to just 17.3% in Europe and 9.8% in Asia.

"The US is an important jurisdictional focus for the company as it is at the forefront of longevity advancements. Trading on the OTCQB will also provide the company with a platform to showcase its innovative solutions and technologies to a wider audience, raising its profile and increasing visibility within the global biotech industry," it explained.

The company also has "close ties" with the University of Rochester in New York, as well as the Buck Institute based in California. As such, the listing will emphasise Genflow's commitment to these relationships.

Upon successful trading on the OTCQB, shares will be made available to US investors, priced in US dollars, thereby easing cross-border trading.

It added that there is no capital raise required with its trading on the OTCQB market, given its "secure financial position." Further, its share will continue to trade on the main market of the London Stock Exchange, under the ticket 'GENF.'

Chief Executive Officer Eric Leire said: "The forefront of advancements in the longevity sector occur in the US and so it is naturally an ambition of ours to increase Genflow's exposure there. Investments and interest in this sector by high profile names including Larry Page and Jeff Bezos, have increased investor curiosity and appetite."

By Sophie Rose, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.